Pfizer announced on Sunday that it intended to invest 520 million euros over five years in France to support the production and research of treatments against the coronavirus, in particular within an industrial site in the Pyrénées-Atlantiques.
The French pharmaceutical subcontractor Novasep will have to manage part of the production of Pfizer’s anti-Covid pill, called Paxlovid. This is an oral treatment against the famous virus whose name is hard to pronounce, with very promising phase II and III results.
A particularly promising treatment
According to Pfizer, the treatment would reduce the risk of hospitalization or death within three days of the onset of symptoms by 89%, reports BFM. 120 million boxes of this drug are expected worldwide in 2022 by the laboratory.
Pfizer also plans to invest in research and development in collaboration with French biotechnology companies, but also to increase the recruitment of French patients in its clinical trials over the next five years.